Prognostic Value of MMP-9 in Ovarian Cancer: A Meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 7, 2013, Pages 4107-4113

  Li, Li Na ^a   Zhou, Xin ^a   Gu, Yang ^a   Yan, Jun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Expression; Meta analysis; MMP 9; Ovarian cancer; Prognosis

Indexed keywords

GELATINASE B; MMP9 PROTEIN, HUMAN;

ARTICLE; ENZYMOLOGY; FEMALE; HUMAN; META ANALYSIS; METABOLISM; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

FEMALE; HUMANS; MATRIX METALLOPROTEINASE 9; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84885446525     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.7.4107     Document Type: Article

References (49)

1. Alshenawy HA (2010). Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelialcancer and relation to patient deaths. Ann Diagn Pathol, 14, 387-95.
2. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, et al (1993). Molecular aspects of tumor cell invasion and metastasis. Cancer, 71, 1368-83.
3. Berman ML (2003). Future directions in the surgical management of ovarian cancer. Gynecol Oncol, 90, S33-9.
4. Clark T, Stewart M, Altman D, et al (2001). A prognostic model for ovarian cancer. Br J Cancer, 85, 944.
5. Davidson B, Goldberg I, Gotlieb WH, et al (1999). High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis, 17, 799-808.
6. Davidson B, Goldberg I, Kopolovic J, et al (1999). Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol, 72, 380-6.
7. Guo BQ, Yu L, Wu SW, et al (2011). Expression of HE4, NF-?b p65, MMP-9 and Their Clinical Signifificance in Epithelial Ovarian Noeplasm. Chinese J Histochem Cytochem, 20, 578-83.
8. Himelstein BP, Canete-Soler R, Berhnhard EJ, et al (1994-1995). Metalloproteinases in tumor progression: the contribution of MMP-9. Invas Metast, 14, 246-58.
9. Huang LW, Garrett AP, Bell DA, et al (2000). Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol, 77, 369-76.
10. Hu J (2011). Expression of MMP2 and MMP9 in tissue of epithelial tumor of ovary and its clinical signifificance. Chin Med Mod Dis China, 9, 208-10.
11. Hu XX, Li DR, Zhang W, et al (2012). Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet, 286, 1537-43.
12. Jean LB, Cortez A, Lesieur B, et al (2012). Expression of MMP-2,-7,-9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer. Oncol Rep, 27, 1049-57.
13. Kamat AA, Fletcher M, Gruman LM, et al (2006). The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res, 12, 1707-14.
14. Kessenbrock K, Plaks V, Werb Z (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 141, 52-67.
15. Lampert K, Machein U, Machein MR, et al (1998). Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Am J Pathol, 153, 429-37.
16. Landis SH, Murray T, Bolden S, et al (1999). Cancer statistics. CA Cancer J Clin, 49, 8-31.
17. Lengyel E, Schmalfeldt B, Konik E, et al (2001). Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol, 82, 291C8.
18. Li DC, Liang LZ, Deng GP (2008). The clinical signifificance of mmp-9 Protein expression in epithelial ovarian carcinoma. Prac J Cancer, 23, 001-2.
19. Li JQ, Shi YF, Zhou HJ, et al (2003). Express ions of MMP-9 and TIMP-1 in epithelial ovarian neoplasms. Prog Obstet Gynecol, 12, 1703.
20. Lou G, Gao Y, Ning XM, et al (2005). Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor. World J Gastroenterol, 11, 5032-6.
21. Määttä M, Santalaa M, Soini Y, et al (2004). Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors. Tumor Biol, 25, 188-92.
22. Murray GI, Duncan ME, Arbuckle E, et al (1998). Matrix metalloproteinases and their inhibitors in gastric cancer. Gut, 43, 791-7.
23. Naylor MS, Stamp GW, Davies BD, et al (1994). Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer, 58, 50-6.
24. Oldenhuis CN, Oosting SF, Gietema JA, et al (2008). Prognostic vs predictive value of biomarkers in oncology. Eur J Cancer, 44, 946-53.
25. Ozalp S, Tanir HM, Yalcin OT, et al (2003). Prognostic value of matrix metalloproteinase (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaec Oncol, 5, 417-20.
26. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
27. Qin M, Hu YQ (2011). VEGF and MMP-9 in ovarian cancer tissues and lymph node invasion and metastasis of transfer correlation. China Med Pharm, 1, 20-1.
28. Remacle AG, Noel A, Duggan C, et al (1998). Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer, 77, 926-31.
29. Shen YF, Xu LL, Li FS, et al (2006). Expression of MMP-9,VEGF,Ki-67 in Krukenberg tumor,epithelial ovarian neoplasm. J Nanjing Med U, 26, 873.
30. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29.
31. Sillanpää S, Anttila M, Voutilainen K, et al (2007). Prognostic signifificance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol, 104, 296-303.
32. Sood AK, Fletcher MS, Coffin JE, et al (2004). Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol, 190, 899-909.
33. Stallings-Mann M, Radisky D (2007). Matrix metalloproteinase-induced malignancy in mammary epithelial cells. Cells Tissues Organs, 185, 104-10.
34. Steels E, Paesmans M, Berghmans T, et al (2001). Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J, 18, 705-19.
35. Sugiura Y, Shimada H, Seeger RC, et al (1998). Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res, 58, 2209-16.
36. Sun SE, Tian LL, Yu HL (2008). Value of MMP-9 and PCNA expression in epithelial ovarian tumor. Matern Child Health Care Chi, 23, 975-7.
37. Tian LL, Zhen JH, Zhang LZ (2007). Expression and signifificance of MMP 9 in epithelial ovarian cancer. J Qiqihar Med Coll, 28, 788-9.
38. Wang FL, Lou YH, Yang XS, et al (2011). Expression of EGFR and MMP-9 in epithelial ovarian cancer and their correlation with prognosis of patients. Prog ObstetGynecol, 20, 689-92.
39. Wang XM, Sun L, Zhen RS, et al (2005). Expression and Clinical Signifificance of MMP -9 and TIMP -1 in Epithelial Ovarian Tumor Using Tissue Microarray Technique. Cancer Res on Pre and Treat, 32, 484-6.
40. Wang XY,Zhang YK,Ren GC (2004). Relation between expression of MMP-2 and MMP-9 and invasion,metastasis of epithelial carcinoma of ovary. Chin J Clin Oncol Rehabil, 11, 406-8.
41. Wu JX, Zhao Y, Jia SJ, et al (2007). Expressions of MMP-2, MMP-3, MMP-9 and CD147 in human ovarian cancer and their clinicopathological s ignifificance. J Chongqing Med U, 32, 1165-8.
42. Xing LY , Cai DG, Fang XH, et al (2007). Study of expression and correlation of cathepsin B and matrix metallo-proteinase-9 in epithelial ovarian tumor. J Xi'an Jiaotong U, 28, 582-4.
43. Yan H, Tan WH (2008). Expression of VEGF and MMP-9 in the epithelial ovavian cavcinoma and its signifificance. Hei Long Jiang Med J, 32, 89-92.
44. Yusuf S, Peto R, Lewis J, et al (1985). Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis, 27, 335-71.
45. Zeng XL, Peng YJ (2010). Expression and clinical signifificance of VEGF, MMP-2 and MMP-9 invovarian carcinoma. Prog Mod Bio, 10, 2322-4.
46. Zeng ZS, Cohen AM, Guillem JG (1999). Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinase 2 and 9 (MMP-2 ad MMP-9) during human colorectal tumorigenesis. Carcinogenesis, 20, 749-55.
47. Zhang DN, Zhang QH, Li HM (2011). Expression and signifificance of MMP 9 and VEGF in ovarian cancer. Chin J Lab Diagn, 15, 1384-95.
48. Zhang HJ, Wu XH, Ruo R (2006). Study on the expressions of vascular endothelial growth factor and its receptors and matrix metalloproteinase 9 in epithelial ovarian cancer. Tianjin Med J, 34, 165-7.
49. Zhang LJ, Tan WH,Yang QH (2007). Expression and signifificance of MMP 9 and laminin receptor in epithelial ovarian neoplasm. Chin J Birth Health Hered, 15, 31-2.